147 related articles for article (PubMed ID: 29187672)
1. Clinical Characteristics and Low Susceptibility to Daptomycin in Enterococcus faecium Bacteremia.
Namikawa H; Yamada K; Shibata W; Fujimoto H; Takizawa E; Niki M; Nakaie K; Nakamura Y; Oinuma KI; Niki M; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Tohoku J Exp Med; 2017 Nov; 243(3):211-218. PubMed ID: 29187672
[TBL] [Abstract][Full Text] [Related]
2. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
[TBL] [Abstract][Full Text] [Related]
3. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
[No Abstract] [Full Text] [Related]
4. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients.
Ghanem G; Hachem R; Jiang Y; Chemaly RF; Raad I
Infect Control Hosp Epidemiol; 2007 Sep; 28(9):1054-9. PubMed ID: 17932826
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.
Kidd JM; Abdelraouf K; Asempa TE; Humphries RM; Nicolau DP
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
7. Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.
Egli A; Schmid H; Kuenzli E; Widmer AF; Battegay M; Plagge H; Frei R; Achermann R; Weisser M
Clin Microbiol Infect; 2017 Feb; 23(2):118.e1-118.e7. PubMed ID: 27746397
[TBL] [Abstract][Full Text] [Related]
8. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions.
Munita JM; Mishra NN; Alvarez D; Tran TT; Diaz L; Panesso D; Reyes J; Murray BE; Adachi JA; Bayer AS; Arias CA
Clin Infect Dis; 2014 Nov; 59(9):1277-80. PubMed ID: 25107294
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure.
DiPippo AJ; Tverdek FP; Tarrand JJ; Munita JM; Tran TT; Arias CA; Shelburne SA; Aitken SL
J Infect; 2017 Mar; 74(3):243-247. PubMed ID: 27845153
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin for highly resistant Enterococcus faecium infection.
Rosin C; Bernsmeier C; Entenza JM; Moreillon P; Frei R; Weisser M; Flückiger U
Swiss Med Wkly; 2012; 142():w13603. PubMed ID: 22736040
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
12. Failure of daptomycin β-Lactam combination therapy to prevent resistance emergence in Enterococcus faecium.
Menon V; Davis R; Shackel N; Espedido BA; Beukers AG; Jensen SO; van Hal SJ
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):120-122. PubMed ID: 29195768
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline.
Polidori M; Nuccorini A; Tascini C; Gemignani G; Iapoce R; Leonildi A; Tagliaferri E; Menichetti F
J Chemother; 2011 Aug; 23(4):240-1. PubMed ID: 21803704
[No Abstract] [Full Text] [Related]
14. Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.
Britt NS; Potter EM; Patel N; Steed ME
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264856
[TBL] [Abstract][Full Text] [Related]
15. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
Cunha BA; Mickail N; Eisenstein L
Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
[TBL] [Abstract][Full Text] [Related]
16. A 10-year profile of enterococcal bloodstream infections at a tertiary-care hospital in Japan.
Suzuki H; Hase R; Otsuka Y; Hosokawa N
J Infect Chemother; 2017 Jun; 23(6):390-393. PubMed ID: 28385565
[TBL] [Abstract][Full Text] [Related]
17. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G
Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia.
Kvirikadze N; Suseno M; Vescio T; Kaminer L; Singh K
Scand J Infect Dis; 2006; 38(4):290-2. PubMed ID: 16709529
[TBL] [Abstract][Full Text] [Related]
19. Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.
Kinnear CL; Patel TS; Young CL; Marshall V; Newton DW; Read AF; Woods RJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718245
[TBL] [Abstract][Full Text] [Related]
20. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
